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ABSTRACT 
 
Objective 
The objective of this systematic review is to examine the efficacy of beta amyloid immunization 
in reducing amyloid plaques and preserving cognitive function in patients with Alzheimer’s 
disease (AD).   
 
Study Design 
Review of three English language randomized, placebo-controlled, double-blind clinical trials 
from 2005-2009. 
 
Data Sources 
Randomized, placebo-controlled, double-blind clinical trials comparing active immunization 
with aggregated human β-amyloid AN1792 and QS-21 (an adjuvant) to placebo were found 
using the Cochrane Database of Randomized Controlled Trials, the Cochrane Database of 
Systematic Reviews, and Ovid MEDLINE.  
 
Outcome(s) Measured 
Cognitive function compared to baseline as measured using three cognitive tests:  the 
Alzheimer’s Disease Assessment Scale Cognitive Sub-scale (ADAS-Cog), which is measured on 
a scale from 0-70 in which a higher score indicates greater impairment; the Folstein Mini-Mental 
State Examination (MMSE), which is measured on a scale from 0-30 and in which a lower score 
indicates greater impairment; and a Neuropsychological Test Battery (NTB) that consisted of 
nine components with varying scores.   
 
Results 
The Bayer trial (phase Ib) showed a positive antibody response to AN1792, but the ADAS-Cogs 
scores increased and MMSE scores decreased in both the active and control groups during the 
study, indicating a decline in cognition.  The Bayer trial did not utilize the NTB.  The Gilman 
trial (phase IIa) showed no significant difference in cognitive function between the active and 
control groups using the ADAS-Cog and MMSE, but the NTB showed cognitive improvement 
compared with the placebo group and a small improvement from baseline when measured at 
month 12.  However, the Gilman trial ended prematurely after 6% of the patients (18/300) 
developed aseptic meningoencephalitis.  The cohort study of the phase IIa trial (Vellas) was 
conducted 4.6 years after immunization with AN1792, and showed no significant change from 
baseline or differences between antibody responders and placebo group using the ADAS-Cog, 
MMSE, and NTB scores.   
 
Conclusions 
This therapy does not appear to maintain nor enhance long-term cognitive function in patients 
with AD.   
 
Key Words  
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INTRODUCTION 
Alzheimer’s disease (AD) is the most common cause of dementia worldwide. It is an 
irreversible, progressive brain disease that affects memory, cognition, personality, and ultimately 
the ability to perform activities of daily living (ADLs). The typical age of onset is after age 60 
and the disease progresses over several years with a mean survival of 8-10 years after the initial 
onset of symptoms
1
.   
The increasing aging population confers significant relevance to AD for patients and 
primary care providers, including Physician Assistants. In the US, AD currently affects about 5.3 
million Americans and is the 6
th
 leading cause of death
2
. The prevalence of AD is about 13% in 
people 65 and older and 44% in people 85 years and older
3
. By 2050, it is estimated that 1 out of 
every 85 persons in the world will be affected by AD
2
. Estimated annual spending in the US on 
care, treatment, and lost productivity of those with AD and caregivers is $172 billion
3
, while 
worldwide estimated annual spending is about $605 billion
4
.  
There is currently no cure for AD; the existing treatments focus on symptom relief and 
retarding the progression of the disease. It is known that AD is characterized by the deposition of 
β-amyloid plaques, an accumulation of neurofibrillary tangles, and neuronal degeneration and 
atrophy of the cerebral cortex leading to a subsequent, progressive loss of cognitive function. 
There is an “amyloid hypothesis” which states that an imbalance in the production (with 
subsequent accumulation and aggregation) of beta-amyloid plaques in the brain is neurotoxic and 
is the main cause of neuronal degeneration and dysfunction
5
. The etiology of the amyloid 
plaques is unknown; only potential risk factors have been identified (i.e., presence of the 
APOE 4 allele, DM type 2, cardiovascular factors, sedentary lifestyle, dietary cholesterol, head 
injury, female gender, viral/bacterial infection, Down’s Syndrome, obstructive sleep apnea). 
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There are no reliable antemortem diagnostic tests available as AD can only be truly confirmed on 
autopsy, and to date there are no measures proven to prevent AD.   
The US Food and Drug Administration has approved five drugs that have been shown to 
temporarily slow the progression of the disease in about half of the population taking the drugs
3
. 
For mild to moderate AD there are the acetylcholinesterase inhibitors donezepil (Aricept
®
), 
galantamine (Razadyne
®
), rivastigmine (Exelon
®
), and tacrine (Cognex®). For moderate to severe 
AD there is an adjunct drug memantine (Namenda
®
) which is an N-methyl-D-aspartate receptor 
blocker. Other treatments include behavioral management such as maintaining familiar 
surroundings, daily moderate cognitive stimulation, and daily routines such as scheduled feeding, 
toileting, etc.               
Current pharmacological treatments for AD provide only modest symptomatic relief and 
questionable prevention of disease progression. Because amyloid-beta (Aβ) peptides that form 
the β-amyloid plaques appear to play a fundamental role in the development of AD, clearance of 
Aβ from the brain is believed to be an important therapeutic strategy for the prevention and 
treatment of AD. Immunotherapy targeting Aβ has been effective in reducing plaque burden and 
improving cognition in transgenic mouse models of AD
6
. The following randomized, placebo-
controlled, double-blind clinical trials and one cohort study to be examined have compared 
active immunization to placebo for changes in cognition, whole-brain volume, safety, and 
tolerability.   
OBJECTIVE  
The objective of this systematic review is to determine whether or not beta amyloid 
immunization preserves cognitive function in patients with Alzheimer’s disease. 
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METHODS 
 The following studies were searched for using the Cochrane Database of Randomized 
Controlled Trials, the Cochrane Database of Systematic Reviews, and Ovid MEDLINE. All of 
the trials were published in the English language by peer-reviewed journals. Key words used in 
searches were: Alzheimer’s disease, amyloid-beta plaque, AN1792, vaccine, immunization, and 
immunotherapy. The inclusion criteria consisted of: 1) the studies were randomized, placebo-
controlled, double-blind clinical trials, 2) patients with Alzheimer’s disease ≤ 85 years, 3) the 
intervention used was immunization with aggregated human β-amyloid AN1792 + QS-21 (an 
adjuvant) +/- 0.4% polysorbate-80 (an emulsifier) and matched placebo, 4) the outcomes 
measured dealt with patient-oriented evidence that matters (POEMS), and 5) the trials had not 
already been used in a systematic review or meta-analysis. The exclusion criteria were studies 
that dealt with disease-oriented evidence (DOEs) and studies that had already been published in 
systematic reviews or meta-analyses. Under these criteria, the following three studies were 
chosen to be analyzed: 1) RCT-Phase 1b (Bayer et al) comparing AN1792 + QS-21 with 
matched placebo (QS-21) and matched placebo (QS-21 + 0.4% polysorbate-80), 2) RCT-Phase 
2a (Gilman et al) comparing AN1792 + QS-21 with matched placebo (QS-21), and 3) a cohort 
study (Vellas et al) of the Bayer et al trial after 4.6 years. Table 1 includes the demographics and 
characteristics of the included studies. The statistics used in the studies were p-values with 
confidence intervals (CIs), and Analysis of Covariance (ANCOVA).   
OUTCOMES MEASURED 
 The three studies used several means to measure outcome, but for the scope of this 
analysis the outcomes measured was cognitive function as compared to baseline and the placebo 
group. The cognitive function tests used were the Alzheimer’s Disease Assessment Scale 
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Table 1 – Demographics and Characteristics of Included Studies 
Study Type #Pts Age  Inclusion Criteria Exclusion Criteria W/D Interventions 
Bayer et 
al, 2005 
RCT 
(double-
blind, 
placebo-
controlled) 
phase 1b 
80 ≤ 85 
yrs 
•Aged ≤ 85 years who lived 
with their caregivers and met 
the criteria for diagnosis of 
probable AD as defined by the 
NINDS-ADRDA.  
•MMSE score of 14-26. 
•Rosen-Modified Hachinski 
Ischemic score of ≤ 4. 
None stated  24 Aggregated 
human beta 
amyloid 
AN1792 (50 or 
225 μg IM) + 
QS-21 (50 or 
100 μg IM +/- 
0.4% 
polysorbate-80) 
Gilman 
et al, 
2005 
 
RCT 
(double-
blind, 
placebo-
controlled) 
phase 2a 
372 50-
85 
yrs 
•Aged 50-85 years who met 
the criteria for diagnosis of 
probable AD as defined by the 
NINDS-ADRDA. 
•MRI brain scan supporting 
the clinical diagnosis of AD.  
•MMSE score of 15-26. 
•Rosen-Modified Hachinski 
Ischemic score of ≤ 4. 
•Pre-existing diagnosis of a clinically 
significant neurologic disease other than 
AD that might affect cognition, major 
psychiatric disorder, systemic illness, or 
symptoms that could affect the subject’s 
ability to complete the study. 
•Hamilton Psychiatric Rating Scale for 
Depression score of > 12. 
• Prior use of an anticonvulsant, 
antiparkinsonian, anticoagulant, narcotic, 
or immunosuppressive medication with 
the potential to affect cognition (unless 
maintained on a stable low to moderate 
dose regime for at least 3 months prior to 
baseline). 
• Prior use of medications for cognitive 
enhancement other than a stable dosing 
regimen of an acetylcholinesterase 
inhibitor for ≥ 6 months.  
96 AN1792 (225 
μg IM) + QS-
21 (50 μg IM) 
Vellas et 
al, 2009 
Cohort 
study of 
Gilman after 
4.6 yrs 
25 50-
85 
yrs 
•Participation in the phase 2a 
study. 
•Positive antibody responders 
(anti-beta amyloid titers ≥ 1: 
2,200) 
•Same as Gilman study 
 
0 Prior 
immunization 
with AN1792 
(225 μg IM) + 
QS-21(50 μg 
IM) 
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Cognitive Sub-scale (ADAS-Cog), the Folstein Mini-Mental State Examination (MMSE), and a 
Neuropsychological Test Battery (NTB) consisting of nine unique components.   
Bayer et al used 64 active and 16 control patients who were given either AN1792 50mcg 
+ QS-21 50mcg, AN1792 50mcg + QS-21 100mcg, AN1792 225mcg + QS-21 50mcg, AN1792 
225mcg + QS-21 100mcg, QS-21 50mcg, or QS-21 100 mcg
7
. Injections were given on day 0, 
weeks 4, 12, and 24, and optional injections at weeks 36, 48, 60, and 72. During the extension 
phase both the active and control immunizations included 0.4% polysorbate-80 to improve 
product stability by preventing AN1792 from precipitating out of solution. ADAS-Cog and 
MMSE were assessed by blinded raters at baseline, weeks 32, 64, 84, and a final visit consisting 
of data from each patient’s last observation carried forward.   
 Gilman et al used 300 active patients who were given AN1792 225mcg + QS-21 50mcg 
+ 0.4% polysorbate-80 and 74 control patients who were given saline injections at day 0, months 
1, 3, 6, 9, and 12
8
. The study was discontinued after 6% of the patients developed aseptic 
meningoencephalitis. The patients only received between 1-3 injections and were enrolled in a 9 
months safety follow-up program. ADAS-Cog, MMSE, and NTB tests were performed by 
blinded raters at baseline, month 6, and month 12.   
 Vellas et al is a cohort study of the Gilman phase IIa trial, which analyzed 129 patients 
given AN1792 and 30 who were given placebo
9
. ADAS-Cog, MMSE, and NTB tests were 
performed by blinded raters during a clinic or home visit.   
RESULTS 
Table 2 shows the results of ADAS-Cog and MMSE testing during the Bayer et al trial.  
The ADAS-Cog test has been the standard primary outcome measure of cognition for AD since 
1984, and a score ≥ 18 indicates greater cognitive impairment10. Using the Folstein MMSE, the 
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highest score possible is 30.  A score of 21-24 indicates mild cognitive impairment, 10-20 is 
moderate, and ≤ 9 is considered severe cognitive impairment11. The patients included in the 
study all were considered to have moderate cognitive impairment. The ADAS-Cog scores show a 
progressive incline in both active and control groups, indicating a decline in cognition and 
therefore no significant efficacy of the immunization. Similarly there was a progressive decline 
in MMSE, also indicating a decline in cognition. The data was analyzed using ANCOVA with 
the baseline value as the covariate and treatment and center as the main effects, reflecting the 
same decline in cognition.   
Table 2 - Effects of AN1792 + QS-21 or QS-21 Alone on ADAS-Cog and MMSE 
Parameter Baseline 
Observed 
Mean (SD) 
Week 32 Week 64 Week 84 Final visit 
Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS-Cog) 
QS-21 only 24.06 (8.71)  
n=16        
27.50 (11.78) 
n=14         
23.17 (10.95)   
n=12       
27.70 (11.23)  
n=10        
28.27 (11.91)   
n=15       
AN1792 + QS-21 22.59 (10.59)         
n=64 
24.61 (11.60)         
n=57 
23.69 (9.43)         
n=48 
26.75 (11.29)         
n=40 
27.02 (12.63)         
n=62 
Mini-Mental State Examination (MMSE) 
QS-21 only 19.75 (4.28)           
n=16      
18.64 (5.17)   
n=14       
16.92 (6.68)     
n=13     
17.17 (6.63)      
n=12    
17.50 (6.19)     
n=14     
AN1792 + QS-21 20.92 (3.38)         
n=64 
18.81 (5.00)    
n=57      
19.04 (5.37)     
n=49     
17.25 (6.35)      
n=44    
17.25 (6.97)         
n=57 
 
Table 3 shows the results of ADAS-Cog, MMSE, and NTB testing during the Gilman et 
al trial. The authors only included patients in the active group who were positive antibody 
responders (19.7%) compared to placebo. There was no difference between the treatment group 
and placebo using the ADAS-Cog and MMSE; both groups showed a negative mean change 
from baseline indicating worsening cognitive function. The high p scores for the ADAS-Cog and 
MMSE indicate no statistical significance between responder and placebo groups. Raw scores on 
the NTB were converted to z-scores and averaged, which was then analyzed using ANCOVA 
with change from baseline z-score as the response, the baseline value as the covariate, and the 
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treatment, MMSE stratum at baseline, and geographic location as independent variables. In the 
NTB analysis, the antibody responders showed a statistically significant lesser cognitive decline. 
Table 3 – Effects of AN1792 (QS-21) or Placebo on ADAS-Cog, MMSE, and NTB  
Parameter Baseline  Month 12  
  Observed mean 
(SD) 
Observed mean change 
from baseline (SD) 
Difference in adjusted 
mean (95% CI) 
p value 
Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS-Cog) 
      Placebo 23.9 (9.9); n=65  -2.7 (6.5); n=53  -0.7 (-3/5, 2.2) 0.641 
      Responder 21.7 (9.6); n=55  -3.8 (7.8); n=44 
Mini-Mental State Examination (MMSE) 
      Placebo 20.3 (3.6); n=65 -1.8 (3.7); n=51 -0.3 (-1.8, 1.1) 0.678 
      Responder 20.7 (3.3); n=55 -1.5 (3.2); n=42 
Neuropsychological Test Battery (NTB) 
      Placebo 0.08 (0.77); n=64 -0.20 (0.45); n=48 -0.23 (-0.41, -0.04) 0.020 
      Responder 0.11 (0.61); n=55 0.03 (0.37); n=36 
 
Table 4 shows the results from the Vellas et al cohort study.  The ADAS-Cog and MMSE 
tests showed no significant differences between antibody responders and placebo. The NTB tests 
were analyzed using an ANCOVA model with change from the Gilman study baseline NTB 
score as the response and the Gilman study baseline NTB as the covariate. NTB scores also 
showed diminished cognitive function.   
 Table 4 – Effects of AN1792 (QS-21) or Placebo on ADAS-Cog, MMSE, and NTB in 
Antibody Responders and Placebo Group 4.6 Years Later 
Parameter Baseline  4.6 Years After Last Immunization 
  Observed mean (SD) 
from Gilman et al 
Observed mean change 
from baseline (SD) 
P value 
Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS-Cog) 
      Placebo 23.9 (9.9); n=65 14.4 (14.2); n=11 0.616 
      Responder 21.7 (9.6); n=55 14.3 (14.0); n=16 
Mini-Mental State Examination (MMSE) 
      Placebo 20.3 (3.6); n=65 -8.3 (5.8); n=18 0.719 
      Responder 20.7 (3.3); n=55 -8.0 (7.8); n=20 
Neuropsychological Test Battery (NTB) 
      Placebo 0.08 (0.77); n=64 -0.751 (0.560); n=10 0.440 
      Responder 0.11 (0.61); n=55 -0.597 (0.626); n=13 
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Table 5 shows the most common adverse events (AEs) reported in two of the trials. In 
Bayer et al, the most common AEs were accidental injury (38.8%), infection (31.3%), and 
confusion (31.3%); the majority of the AEs were considered mild to moderate
7
. Ten patients 
prematurely withdrew from the study due to AEs and five patients died during the study period 
but none of the deaths were considered to be directly related to the study. There were no safety 
concerns at the end of this trial to prevent the commencement of a larger phase II trial. In Gilman 
et al, the most common AEs were accidental injury (15.3% placebo, 13.7% active), infection 
(12.5% placebo, 19.0% active), and headache (9.7% placebo, 17.3% active)
 8
. Eighteen of the 
300 active patients (6%) developed encephalitis. Thirteen of them were antibody responders, and 
all 18 were still alive one year after the onset of symptoms
12
. Seventy-seven of the 300 active 
patients and 19/72 placebo patients withdrew prematurely due to AEs. Seven patients died during 
the follow-up study period, and one antibody non-responder’s death was considered to be related 
to the treatment. Vellas et al collected data of serious adverse events (SAEs) that had occurred 
since the end of the Gilman et al study, but did not report specific SAES, only overall incidence. 
The occurrence of SAEs in the placebo group was 33.3% versus 40.0% in the antibody responder 
group; no SAEs were considered to be related to treatment and no new cases of encephalitis were 
observed
9
. 
Table 5 – Profile of Adverse Events 
 
 
 
 
 
 
  Bayer et al                 
N (%) 
Gilman et al                  
N (%) 
  Placebo AN1792 Placebo AN1792 
Accidental injury 6 (37,5) 25 (39.1) 11 (15.3) 41 (13.7) 
Confusion 5 (31.3) 20 (31.3) 6 (8.3) 35 (11.7) 
Infection 5 (31.3) 20 (31.3) 9 (12.5) 57 (19.0) 
Headache 3 (18.8) 7 (10.9) 7 (9.7) 52 (17.3) 
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The adverse event rates in the control group (control event rate, or CER) and the active or 
experimental event rate (EER) are shown in Table 6. The experimental group shower higher 
rates of adverse events in the Gilman et al and Vellas et al studies, but in the Bayer et al trial the 
adverse event rate in the control group was 100%. The negative relative risk increase (RRI) in 
the Bayer et al trial means an adverse event is less likely to occur in the experimental group than 
in the control group. Specifically, an adverse event was 8.3% more likely to occur in the 
experimental group as seen in the Gilman et al trial. The absolute risk increase (ARI) shows the 
absolute difference in risk between the experimental and control groups. Numbers needed to 
harm (NNH) is a measure of how many patients need to be exposed to a treatment to cause harm 
in one patient. In the Gilman et al trial, for every 15 patients immunized with AN1792, one 
patient experienced an adverse event. The negative NNH in the Bayer et al trial means that for 
every 32 patients immunized, one less experienced an adverse event.    
Table 6 – Analysis of Outcomes and Numbers Needed to Harm in Patients Immunized with 
AN1792 (QS-21) vs. Placebo 
Study CER EER RRI ARI NNH 
Bayer et al 100.0% 96.9% -3.1% -3.1% -32 
Gilman et al 81.9% 88.7% 8.3% 6.8% 15 
Vellas et al 33.3% 40.0% 21.0% 6.7% 5 
            
DISCUSSION 
The Bayer et al trial did not show any improvement in cognitive function or a slowing of 
the progression of AD, and demonstrated a few shortcomings. Out of all the patients who were 
actively treated, about 53.1% had a positive antibody titer during the study
7
. It is difficult to 
assess the efficacy of an immunization in which only half of the patients mount an immune 
response. When the ADAS-Cog and MMSE were assessed, the final visit utilized data from each 
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patient’s last observation carried forward (LOCF). This method of analysis is based on 
assumption and may bias the estimate of treatment efficacy
13
. 
In the Gilman et al trial, even fewer active group patients mounted an antibody response 
(20%), although the trial ended prematurely after 1-3 injections
8
. A supplement from Bayer et al 
to the Gilman et al trial was the addition of 0.4% polysorbate-80 to the active group injection. It 
has been suggested that this may have been responsible for the meningoencephalitis by creating 
an inflammatory T cell response, rather than the formation of antibodies
14
. 
A major limitation to the Vellas et al trial was the lack of patients able to participate in 
the study almost five years later. The original trial (Gilman et al) featured 300 active patients, 
and 60 of those were antibody responders. Vellas et al was only able to procure 25 of those 
responders. The Gilman et al trial also featured 74 placebo patients, while Vellas et al included 
only 30 placebo patients. The placebo group may also been biased as the patients who were still 
able to perform cognitive function tests would be inherently less impaired than their placebo 
counterparts who were already too demented to participate. In addition, that the majority of all 
participants in this study were currently taking acetylcholinesterase inhibitors or memantine, 
which may have also been a confounding factor.   
Finally, among each of the trials examined, many of the placebo group patients 
experienced a significant amount of AEs. In Bayer et al, some AEs occurred twice as often in the 
negative antibody responders, and therefore may have been associated with the progression of 
AD or working with an aging population for an extended period of time. 
CONCLUSION 
It appears that active immunization with beta amyloid is ineffective at preserving the rate 
of cognitive decline in patients with Alzheimer’s disease. Although the Gilman et al trial found 
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that the NTB analysis showed a statistically significant lesser cognitive decline in the antibody 
responders than the placebo group, Vellas et al showed that 4.6 years later there was no 
significant difference observed in change from baseline between antibody responders and 
placebo patients.  
The major flaw in the basic design of the study is the enormous difference in comparing 
human genetics to transgenic mice. Mice have much less genetic variability. Their plaques are 
composed of a different chemical composition which is more soluble and easier to remove. In the 
future, new therapies should be tested extensively on species that are genetically closer to 
humans.   
The Vellas et al trial did demonstrate significantly less impairment in ADLs and 
dependence on caregivers in the antibody responders, which was not discussed in this analysis 
but could potentiate further support for immunotherapy research in patients with mild to 
moderate AD. More current immunotherapy research is focusing on passive immunization, and 
there are several trials underway at the moment. The most advanced is a phase III trial with 
bapineuzumab, a humanized anti-amyloid beta monoclonal antibody, which as of December 
2010 is still actively recruiting participants
15
.  
The ability to control the immune system to clear amyloid beta plaques could be 
promising in not only the treatment of AD but many other neurodegenerative diseases that also 
are attributed to abnormal protein formation, such as Creutzfeldt–Jakob disease (CJD), 
Huntington’s chorea, and Parkinson’s disease. Future research in immunotherapy could 
potentially provide a breakthrough in disease-altering therapy for many diseases of aging, which 
are increasing in prevalence as the world population continues to age. 
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